The grant will support the consortium's ongoing efforts to clinically validate data analysis software for monitoring treatment responses to cancer vaccines.
The Universal Influenza Vaccine Initiative, led by Vanderbilt and the Human Vaccines Project, has turned to omics and AI to create more effective flu vaccines.
Neon Therapeutics is sponsoring a Phase Ib trial of neoantigen-based vaccines in combination with anti-PD-1 treatment in melanoma, lung cancer, and bladder cancer.
The two companies plan to combine their respective gene editing and neoantigen discover technologies in order to develop new T cell therapies for cancer patients.
Two independent research teams published findings for melanoma patients treated with vaccines developed against neo-antigens in their tumors that sequencing uncovered.
